Indivior PLC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

26 Feb 2026

INDV

10-K: Indivior's 2025 Annual Report: SUBLOCADE Drives Growth

Indivior Pharmaceuticals reports strong 2025 revenue growth driven by SUBLOCADE, alongside strategic restructuring and U.S. domestication.

NASDAQ

3 Mar 2025

INDV

Indivior PLC

10-K: Indivior PLC Navigates Opioid Crisis with Focus on SUBLOCADE, Faces Legal and Competitive Challenges

Indivior PLC's 2024 10-K filing highlights its focus on substance use disorder treatments, particularly SUBLOCADE, while addressing ongoing litigation, competitive pressures, and regulatory compliance.